NCH2 Fundamental Analysis - THYSSENKRUPP NUCERA AG & CO

Fundamental Rating

NCH2 gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 41 industry peers in the Construction & Engineering industry. While NCH2 seems to be doing ok healthwise, there are quite some concerns on its profitability. NCH2 shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

NCH2 had positive earnings in the past year.

In the past year NCH2 had a positive cash flow from operations.

NCH2 had positive earnings in each of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: NCH2 reported negative operating cash flow in multiple years.

1.2 Ratios

With a Return On Assets value of 1.09%, NCH2 is not doing good in the industry: 75.61% of the companies in the same industry are doing better.

NCH2 has a worse Return On Equity (1.80%) than 78.05% of its industry peers.

The Return On Invested Capital of NCH2 (0.08%) is worse than 90.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	1.09%
ROE	1.8%
ROIC	0.08%

ROA(3y)1.36%

ROA(5y)2.95%

ROE(3y)2.51%

ROE(5y)5.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 1.49%, NCH2 is doing worse than 73.17% of the companies in the same industry.

NCH2's Profit Margin has declined in the last couple of years.

NCH2 has a Operating Margin of 0.09%. This is amonst the worse of the industry: NCH2 underperforms 90.24% of its industry peers.

Looking at the Gross Margin, with a value of 11.22%, NCH2 is doing worse than 87.80% of the companies in the same industry.

NCH2's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	0.09%
PM (TTM)	1.49%
GM	11.22%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y-42.36%

PM growth 5YN/A

GM growth 3Y-21.27%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NCH2 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

The number of shares outstanding for NCH2 remains at a similar level compared to 1 year ago.

Compared to 1 year ago, NCH2 has an improved debt to assets ratio.

2.2 Solvency

NCH2 has an Altman-Z score of 3.13. This indicates that NCH2 is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 3.13, NCH2 is doing good in the industry, outperforming 78.05% of the companies in the same industry.

A Debt/Equity ratio of 0.03 indicates that NCH2 is not too dependend on debt financing.

The Debt to Equity ratio of NCH2 (0.03) is better than 97.56% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	3.13

ROIC/WACC0.01

WACC7.3%

2.3 Liquidity

NCH2 has a Current Ratio of 2.48. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.48, NCH2 belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.

NCH2 has a Quick Ratio of 2.04. This indicates that NCH2 is financially healthy and has no problem in meeting its short term obligations.

With an excellent Quick ratio value of 2.04, NCH2 belongs to the best of the industry, outperforming 95.12% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.48
Quick Ratio	2.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 175.00% over the past year.

Measured over the past years, NCH2 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -19.70% on average per year.

The Revenue has decreased by -4.88% in the past year.

Measured over the past years, NCH2 shows a very strong growth in Revenue. The Revenue has been growing by 39.21% on average per year.

EPS 1Y (TTM)175%

EPS 3Y-19.7%

EPS 5YN/A

EPS Q2Q%-120%

Revenue 1Y (TTM)-4.88%

Revenue growth 3Y39.21%

Revenue growth 5YN/A

Sales Q2Q%-21.93%

3.2 Future

NCH2 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 60.71% yearly.

NCH2 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.19% yearly.

EPS Next Y-9.54%

EPS Next 2Y30.42%

EPS Next 3Y48.22%

EPS Next 5Y60.71%

Revenue Next Year3.05%

Revenue Next 2Y-4.83%

Revenue Next 3Y3.38%

Revenue Next 5Y12.19%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 95.59, which means the current valuation is very expensive for NCH2.

Based on the Price/Earnings ratio, NCH2 is valued a bit more expensive than the industry average as 75.61% of the companies are valued more cheaply.

When comparing the Price/Earnings ratio of NCH2 to the average of the S&P500 Index (27.29), we can say NCH2 is valued expensively.

A Price/Forward Earnings ratio of 68.68 indicates a quite expensive valuation of NCH2.

Compared to the rest of the industry, the Price/Forward Earnings ratio of NCH2 indicates a rather expensive valuation: NCH2 more expensive than 82.93% of the companies listed in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 22.80, NCH2 is valued quite expensively.

		Industry Rank	Sector Rank
PE	95.59
Fwd PE	68.68

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NCH2 is valued expensively inside the industry as 80.49% of the companies are valued cheaper.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	61.51

4.3 Compensation for Growth

NCH2's earnings are expected to grow with 48.22% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.42%

EPS Next 3Y48.22%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NCH2!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

THYSSENKRUPP NUCERA AG & CO

FRA:NCH2 (9/25/2025, 12:36:26 PM)

10.515

-0.02 (-0.24%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryConstruction & Engineering

Earnings (Last)08-13 2025-08-13/bmo

Earnings (Next)N/A N/A

Inst Owners18.78%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.33B

Analysts74.74

Price Target12.19 (15.93%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-9.09%

Min Revenue beat(2)-12.43%

Max Revenue beat(2)-5.74%

Revenue beat(4)1

Avg Revenue beat(4)-2.5%

Min Revenue beat(4)-12.43%

Max Revenue beat(4)10.74%

Revenue beat(8)1

Avg Revenue beat(8)-6.07%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-2.45%

PT rev (3m)-2.33%

EPS NQ rev (1m)0%

EPS NQ rev (3m)366.67%

EPS NY rev (1m)0%

EPS NY rev (3m)55.87%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-16.46%

Revenue NY rev (1m)-0.31%

Revenue NY rev (3m)-1.68%

Valuation

		Industry Rank	Sector Rank
PE	95.59
Fwd PE	68.68
P/S	1.46
P/FCF	N/A
P/OCF	69.17
P/B	1.76
P/tB	1.94
EV/EBITDA	61.51

EPS(TTM)0.11

EY1.05%

EPS(NY)0.15

Fwd EY1.46%

FCF(TTM)-0.05

FCFYN/A

OCF(TTM)0.15

OCFY1.45%

SpS7.22

BVpS5.97

TBVpS5.42

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	1.09%
ROE	1.8%
ROCE	0.1%
ROIC	0.08%
ROICexc	0.58%
ROICexgc	1.54%
OM	0.09%
PM (TTM)	1.49%
GM	11.22%
FCFM	N/A

ROA(3y)1.36%

ROA(5y)2.95%

ROE(3y)2.51%

ROE(5y)5.96%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3Y-42.36%

PM growth 5YN/A

GM growth 3Y-21.27%

GM growth 5YN/A

F-Score4

Asset Turnover0.73

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	2.31
Cap/Depr	261%
Cap/Sales	2.86%
Interest Coverage	1
Cash Conversion	177.78%
Profit Quality	N/A
Current Ratio	2.48
Quick Ratio	2.04
Altman-Z	3.13

F-Score4

WACC7.3%

ROIC/WACC0.01

Cap/Depr(3y)106.05%

Cap/Depr(5y)76.37%

Cap/Sales(3y)0.81%

Cap/Sales(5y)0.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)175%

EPS 3Y-19.7%

EPS 5YN/A

EPS Q2Q%-120%

EPS Next Y-9.54%

EPS Next 2Y30.42%

EPS Next 3Y48.22%

EPS Next 5Y60.71%

Revenue 1Y (TTM)-4.88%

Revenue growth 3Y39.21%

Revenue growth 5YN/A

Sales Q2Q%-21.93%

Revenue Next Year3.05%

Revenue Next 2Y-4.83%

Revenue Next 3Y3.38%

Revenue Next 5Y12.19%

EBIT growth 1Y126.55%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year106.26%

EBIT Next 3Y58.82%

EBIT Next 5Y41.41%

FCF growth 1Y-341.18%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-376.92%

OCF growth 3YN/A

OCF growth 5YN/A

THYSSENKRUPP NUCERA AG & CO (NCH2.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens